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ABSTRACT
Apoptosis occurs at an extraordinary rate in the human body and the effective clearance of dead cells (efferocytosis) is necessary to maintain
homeostasis and promote healing, yet the contribution and impact of this process in bone is unclear. Bone formation requires that bonemarrow
stromal cells (BMSCs) differentiate into osteoblasts which direct matrix formation and either become osteocytes, bone lining cells, or undergo
apoptosis. A series of experiments were performed to identify the regulators and consequences of macrophage efferocytosis of apoptotic
BMSCs (apBMSCs). Bonemarrow derivedmacrophages treated with the anti-inflammatory cytokine interleukin-10 (IL-10) exhibited increased
efferocytosis of apBMSCs compared to vehicle treated macrophages. Additionally, IL-10 increased anti-inflammatory M2-like macrophages
(CD206þ), and further enhanced efferocytosis within the CD206þ population. Stattic, an inhibitor of STAT3 phosphorylation, reduced the
IL-10-mediated shift inM2macrophage polarization and diminished IL-10-directed efferocytosis of apBMSCs bymacrophages implicating the
STAT3 signaling pathway. Cell culture supernatants and RNA from macrophages co-cultured with apoptotic bone cells showed increased
secretion of monocyte chemotactic protein 1/chemokine (C-C motif) ligand 2 (MCP-1/CCL2) and transforming growth factor beta 1 (TGF-b1)
and increased ccl2 gene expression. In conclusion, IL-10 increases M2 macrophage polarization and enhances macrophage-mediated
engulfment of apBMSCs in a STAT3 phosphorylation-dependent manner. After engulfment of apoptotic bone cells, macrophages secrete
TGF-b1 and MCP-1/CCL2, factors which fuel the remodeling process. A better understanding of the role of macrophage efferocytosis as it
relates to normal and abnormal bone turnover will provide vital information for future therapeutic approaches to treat bone related diseases.
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The critical process of bone formation depends on the lifespanand activity of osteoblasts lining the bone surface. Three fates
have been described for osteoblasts: they either become osteocytes
embedded in mineralized matrix, bone-lining cells which form
layers over bone surfaces and at remodeling sites, or they undergo
programmed cell death (apoptosis). Of the osteoblasts initially at
remodeling sites, 30–50% become osteocytes and bone-lining cells,
which leaves a large percentage of cells thought to undergo
apoptosis [Jilka et al., 1998]. The course of events after osteoblast
apoptosis has been under appreciated. This is in part due to the
inability of assays to accurately detect and quantify apoptotic
osteoblasts readily undergoing apoptosis. In normal physiology, cell
death is followed by rapid and efficient removal of apoptotic cells by
phagocytic cells, predominantly macrophages. This process of
apoptotic cell recognition and clearance is termed efferocytosis
[Ravichandran and Lorenz, 2007].
Macrophages are immune cells known for their role in infection
and inflammation. A focus on their role in bone has only recently
emerged [Sinder et al., 2015]. Macrophages are prominent players in
bone homeostasis and are highly implicated in fracture healing
[Chang et al., 2008; Alexander et al., 2011; Cho et al., 2014]. They are
often found at sites of remodeling, and are intimately associatedwith
bone forming osteoblastic cells. Additionally, macrophage numbers
increase significantly in fracture sites, and bone repair is severely
diminished after tibial injury in macrophage-ablated mouse models
[Alexander et al., 2011]. Apoptotic cells increase in sites of injury,
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and a crucial component of the healing process is the effective
clearance of these cells by phagocytes, including macrophages. The
recognition and subsequent efferocytosis of dead and dying cells
leads to the secretion of anti-inflammatory cytokines such as TGF-b
and IL-10 [Voll et al., 1997; Fadok et al., 1998], as well
as osteoinductive factors including osteopontin, and BMP-2
[Champagne et al., 2002; Takahashi et al., 2004; Honda et al.,
2006]. The process of efferocytosis has been extensively studied in
other tissues. Recently, macrophages were found to efferocytose
apoptotic osteoblasts [McCauley et al., 2014] yet the impact of
efferocytosis in bone has not been clearly defined.
Macrophages have been shown to polarize into two popula-
tions: classically activated M1 macrophages and alternatively
activated M2 macrophages. M2 macrophages are present during
the resolution phase of inflammation and are responsible for anti-
inflammatory cytokine production and enhanced efferocytosis
[Xu et al., 2006; Bystrom et al., 2008]. In the presence of the
anti-inflammatory cytokines IL-4 and IL-10, macrophages polarize
to M2-like macrophages [Mantovani et al., 2004], and increase
apoptotic lymphocyte and apoptotic neutrophil clearance [Ogden
et al., 2005; Lingnau et al., 2007]. IL-10 is an important bone
cytokine which inhibits osteoclastogenesis [Xu et al., 1995] and
exhibits a protective role in periodontal disease [Moretti et al.,
2015]. Furthermore, IL-10 deficient mice exhibit low bone mass
phenotypes with reduced bone formation compared to wild-type
controls [Xu et al., 1995; Dresner-Pollak et al., 2004]. To our
knowledge, the role of IL-10-induced efferocytosis in bone has not
been investigated.
Additonally, it is unclear which factors regulate the clearance
of apoptotic bone cells by bone resident macrophages and how
macrophages respond to the englulfment of an apoptotic bone
cell. The apoptotic cell identity can impact the response elicited
by the phagocyte and the response of a bone marrow macrophage
to an apoptotic bone cell is of interest to the present work. This
study aimed to determine factors and signaling which affect
macrophage efferocytosis of apoptotic osteoblastic cells and




All animals were maintained in accordance with institutional
animal care and use guidelines, and experimental protocols were
approved by the Institutional Animal Care and Use Committee of
the University of Michigan. C57BL/6J (The Jackson Laboratory,
Bar Harbor, ME) mice were used for in vitro experiments unless
otherwise indicated. Human CD68-GFP reporter mice (hCD68-GFP)
mice were generously provided by Dr. Ajay Chawla (University of
California San Francisco). hCD68-GFP mice were generated by
cloning a cDNA fragment encoding EGFP (from pEGFP-N1 vector,
Invitrogen) into the 1,265 vector containing human CD68
promoter (2.9 kb). DNA was then excised from the vector
and injected into mouse oocytes by pro-nuclear injection [Iqbal
et al., 2014].
CELL CULTURE
Primary bone marrow cells were collected from 4- to 8-week old
C57BL/6J or hCD68-GFP mice. Bone marrow-derived macrophages
(BMMs) were differentiated in vitro from bone marrow flush in
a-MEM medium (10% FBS, Pen/Strep, glutamine) with murine
M-CSF (30 ng/mL eBioscience) for 6 days. At day 7, macrophages
were plated at 2.5 105 cells/well in 12-well plates (for efferocytosis
assays) or 1.5 106 cells/well in 6-well plates (for protein/RNA).
Bone marrow stromal cells (BMSCs) were derived from bone marrow
flush and cultured in a-MEM medium (20% FBS, Pen/Strep,
glutamine) containing 10 nM dexamethasone (Sigma) and used at
passage 1–2. Bone marrow neutrophils were isolated as previously
described [Swamydas and Lionakis, 2013]. Briefly, bonemarrowwas
flushed from 8- to 12-week old C57BL/6J mice with RPMI
supplemented with 10% FBS and 2mM EDTA, red blood cells lysed
using 0.2% NaCl, and neutrophils separated by density gradient
centrifugation (Histopaque 1119 and Histopaque 1077). Neutrophils
were harvested at the interface of the Histopaque 1119 and
Histopaque 1077 layers and confirmed using FACs anaylsis for
CD11bþLy6Gþ cells.
MACROPHAGE TREATMENT
All recombinant murine proteins were obtained from R&D
Systems. BMMs were treated at day 8 with rmIL-10 (0.1–100 ng/mL),
rmCCL2/MCP-1 (10 ng/mL), rmMFG-E8 (10 ng/mL), sIL-6R
(100 ng/mL), or vehicle (0.5% BSA in 1X PBS) for 4–24 h in low
serum containing media (0.5% FBS). In a set of experiments BMMs
were pre-treated with an inhibitor of pSTAT3 (Stattic, 6.25mM,
CalBiochem) or DMSO (vehicle) 2 h prior to rmIL-10 treatment.
EFFEROCYTOSIS ASSAY
BMSCs were stained with CellTracker Deep Red (APCþ, Invitrogen)
and exposed to UV light for 30min to induce apoptosis. Apoptotic
BMSCs (apBMSCs) were recovered for 2 h at 37°C, enumerated via
trypan blue exclusion (confirming cell death), and added to BMM
cultures at a 1:1 ratio for 0.5–6 h. BMMs co-cultured with apBMSCs
were harvested and stained with F4/80-FITC (Abd Serotec, CI:A3-1),
fixed with 1% formalin and efferocytosis was assessed via flow
cytometric (FACs) analyses (BD FACSAriaTM III) for double labeled
cells (FITCþAPCþ) reflecting engulfment. Macrophages cultured
alone were harvested and stained with the following macrophage-
specific antibodies: F4/80 FITC (CI:A3-1, BIORAD), CD86 PE (GL-1,
Biolegend), and CD206 PE (C068C2, Biolegend). Cells were fixed,
permeabilized with Permeabilization Buffer (Biolegend), incubated
with CD68 PE (Y1/82A, Biolegend) and assessed via FACs analyses.
CONFOCAL MICROSCOPY
BMMs from hCD68-GFP mice were plated in 1.5-mm
coverglass chambers (8 104 cells/well), treated for 24 h with
vehicle or rmIL-10 (10 ng/mL) and apBMSCs (stained with
CellTracker DeepRed) were added at a 1:1 ratio to BMMs for
1–24 h and fixed with ice-cold methanol for 20min. Cells were then
washed with PBS and covered with ProLong1 Gold antifade reagent
with DAPI (Life Technologies). Confocal microscopy images were
analyzed using the Leica inverted SP5X confocal microscope system
with two-photon film and Leica software (Leica Microsystems).
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MOUSE INFLAMMATION ANTIBODY ARRAY
BMMs were plated into 6-well dishes (1.5 106 cells/well), then
co-cultured with or without apBMSCs at a 1:1 ratio in a-MEM
(0.25% FBS). Supernatants were collected after 18 h and proteins
were analyzed using the mouse inflammation antibody array C1
(catalog no. AAM-INF-1–8, RayBiotech, Inc.) per manufacturer0s
instructions.
TGF-b1 ELISA
Supernatants were collected from BMMs alone, BMMs/apBMSCs or
BMMs/apNeutrophils after 18 h of co-culture. TGF-b1 protein levels
in culture supernatants were measured with the Quantikine mouse
TGF-b1 ELISA (R&D systems) per manufacturer0s instructions.
Briefly, acid-activated supernatant samples, standards, and controls
were added to anti-mouse TGF-b1 antibody pre-coated microplates
and incubated at room temperature for 2 h. Wells were washed and
incubated with TGF-b1 conjugate for 2 h, washed and substrate
solution added for 30min. Stop solution was added and A450 values
(corrected with A570) were measured using an EZ Read 400
microplate reader (Biochrom).
QRT-PCR
Total RNA was isolated from BMMs alone, apBMSCs alone, and
BMM/apBMSC co-culture after 18 h using the Qiagen RNeasy Mini
Kit. Reverse transcription PCR was conducted, and the cDNA
products were amplified and detected using TaqMan Universal PCR
master mix (Applied Biosystems) and TaqMan probes, including
mouse Ccl2 (Mm00441242_m1) and mouse Actb (Mm02619580_g1)
as an endogenous control. Realtime PCRwas analyzed onABI PRISM
7700 (AppliedBiosystems).
STATISTICAL ANALYSES
Statistical analyses were performed by unpaired Student0s t test to
compare two groups or ANOVA to compare three or more groups
with a significance of P< 0.05. Data are presented as mean S.E.
RESULTS
IL-10 ENHANCES BONE MARROW DERIVED MACROPHAGE
ENGULFMENT OF APOPTOTIC BONE MARROW STROMAL CELLS
To investigate the impact of IL-10 on macrophage-mediated
efferocytosis of apoptotic bone cells, bone marrow macrophages
(BMMs) were treated with IL-10 and efferocytosis of apoptotic
bone marrow stromal cells (apBMSCs) was determined. BMMs
(F4/80-FITCþ) were co-cultured with apBMSCs (DeepRed-APCþ)
and double positive (FITCþAPCþ) cells were quantified using flow
cytometric cell sorting, reflecting engulfment (Fig. 1A, left panel).
Engulfment was confirmed by ImageStream analysis, identifying
double-positive cells as macrophages associated with apBMSCs
(Fig. 1A). To assess the effect of various cytokines on efferocytosis,
BMMs were treated with IL-10, CCL2, MFG-E8, and sIL-6R for 24 h
and efferocytosis of apBMSCs measured after 1 h of co-culture.
IL-10 enhanced engulfment of apBMSCs by 22% and in a dose-
dependent manner (Fig. 1B and C), whereas MCP1, MFG-E8, and
sIL-6R did not demonstrate significant changes in efferocytosis at
that time point. To determine the optimum IL-10 treatment length,
BMMs were treated for 4–48 h with IL-10. BMMs treated for 24 h
with IL-10 displayed increased efferocytosis compared to shorter
treatment times (Fig. 1D). Macrophages treated with IL-10 for 24 h
showed enhanced efferocytosis when co-cultured for shorter
durations (0.5–2 h) compared to longer co-cultures (6 h), suggest-
ing IL-10 increased the rate of efferocytosis (Fig. 1E). IL-10
treatment of BMMs enhanced engulfment of apBMSCs in a time
and dose-dependent manner.
IL-10 POLARIZES BONE MARROW DERIVED MACROPHAGES TO
M2-LIKE PHENOTYPE WITH ENHANCED EFFEROCYTIC CAPACITY
Macrophages are described as classically (M1) or alternatively (M2)
activated. M2 polarized macrophages are resolving cells with higher
efferocytic capacity than M1 macrophages [Xu et al., 2006]. To
determine the impact of IL-10 treatment on BMM phenotypes, equal
numbers of BMMs were treated with IL-10 for 24 h and assessed for
M1 (F4/80þCD86þ) and M2 (F4/80þCD206þ) polarization. IL-10 did
not affect cell number or viability (Fig. 2A), mature (CD68þ) or M1
macrophages (Fig. 2B). Treatment with IL-10 significantly increased
M2 polarization of BMMs (Fig. 2C). This effect of IL-10 is consistent
with previous reports [Goerdt and Orfanos, 1999; Mantovani et al.,
2004], however, the impact of IL-10 within the M2 population is
unclear. To investigate the role of IL-10 on altering efferocytosis
within the CD206þ population, efferocytosis of apBMSCs by CD206þ
cells was measured. IL-10 increased the percentage of CD206þ cells
that efferocytosed apBMSCs (Fig. 2D), suggesting that IL-10 not only
polarized BMMs to M2 macrophages, but also specifically enhanced
their efferocytic ability.
IL-10 INCREASES EFFEROCYTOSIS IN A STAT3 ACTIVATION
DEPENDENT MANNER
IL-10 signals through the JAK/STAT pathway and inhibition of
JAK/STAT signaling has been shown to decrease efferocytosis [Soki
et al., 2014]. To measure the effect of JAK/STAT pathway inhibition
on IL-10 induced efferocytosis, BMMs were pre-treated with the
phospho-STAT3 (pSTAT3) inhibitor Stattic prior to IL-10 treatment
and efferocytosis measurement. BMMs were isolated from mice
which express GFP under the human CD68 promoter to visualize
CD68þ (mature phagocytic) cells (Fig. 3A). Macrophages harvested
from the hCD68-GFP mice displayed increased efferocytosis of
apBMSCs following IL-10 treatment as measured by FACs analysis
and confocal microscopy (Fig. 3B and C). BMMs pre-treated for 2 h
with Stattic and subsequently treated with IL-10 had reduced
efferocytosis of apBMSCs compared to DMSO control treated
macrophages (Fig. 3D). Macrophages pre-treated with Stattic
followed by vehicle treatment also displayed decreased efferocytosis
compared to controls suggesting some baseline efferocytosis
in vehicle treated macrophages requires signaling through the
JAK/STAT pathway, likely by other cytokine signaling. To
investigate the role of JAK/STAT signaling in IL-10 induced M2
polarization, BMMs were treated with Stattic for 2 h followed by
IL-10 treatment and assessed for CD206þ (M2 polarization). In
vehicle treated BMMs, Stattic did not alter the M2 population;
however, Stattic treatment prior to IL-10 treatment significantly
reduced the IL-10 mediated M2 shift in macrophage polarization
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(Fig. 3E) suggesting that IL-10 shifts macrophage polarization and
enhances efferocytosis of apBMSCs via signaling through JAK/STAT
pathway.
MACROPHAGES SECRETE MCP-1/CCL2 AND TGF-b1 IN RESPONSE
TO APOPTOTIC BONE MARROW STROMAL CELLS
Macrophages release factors when engulfing apoptotic cells that
signal to surrounding cells [Fadok et al., 1998, 2001; Kim et al.,
2004]. To determine the response of macrophages to apBMSCs,
BMMs were cultured alone or with apBMSCs for 18 h and
supernatants harvested for analysis of secreted proteins. Super-
natants harvested from co-culture of BMMs with apBMSCs showed
significantly increased secreted CCL2 levels compared to macro-
phages cultured alone (Fig. 4A). RNA harvested from macrophages
co-cultured with apBMSCs also showed increased ccl2 gene
expression (Fig. 4B) compared to BMMs alone or BMMs
co-cultured with apoptotic neutrophils. In other tissues, TGF-b1
is an important anti-inflammatory cytokine released from macro-
phages after efferocytosis [Fadok et al., 1998]. Supernatants from
macrophages cultured with apBMSCs versus macrophages alone or
versus macrophages cultured with apoptotic neutrophils displayed
increased total secreted TGF-b1 levels (Fig. 4C). Hence, in response
to engulfment of apoptotic bone cells, bone marrow macrophages
secrete the anti-inflammatory cytokine TGF-b1 and chemokine
CCL2, which are both important factors related to bone
homeostasis.
DISCUSSION
Patients exhibiting increased inflammation associated with diseases
such as rheumatoid arthritis and inflammatory bowel disease are
often at a higher risk of generalized osteoporosis and increased
fracture risk [Minne et al., 1984; Deodhar and Woolf, 1996;
Andreassen et al., 1997]. Chronic inflammation is associated with
systemic overproduction of pro-inflammatory mediators, which are
thought to play a role in decreasing bone formation [Pfeilschifter
et al., 1987]. Periodontal disease activates macrophages and triggers
systemic inflammation of the vasculature and atherosclerotic signs
[Miyajima et al., 2014]. Macrophages are immune cells which
Fig. 1. IL-10 treatment enhanced efferocytosis of apoptotic bone marrow stromal cells (apBMSCs) by bone marrow derived macrophages (BMMs). (A) BMMs were stained for
F4/80-FITC and apBMSCs stained with Cell Tracker Deep Red, co-cultured for 1hr and analyzed via flow cytometry. Representative fluorescence-activated cell sorting (FACs) dot
plots (left) indicate macrophages alone (green gate), apBMSCs alone (red gate), or macrophages with internalized apBMSCs (yellow gate). Representative photo from Image
Stream which captures single cell images showing either single cells or engulfment. (B) BMMs treated for 24 h with vehicle, rmIL-10 (10 ng/mL), rmMCP-1 (10 ng/mL),
rmMFG-E8 (500 ng/mL), or sIL-6R (500 ng/mL) and co-cultured with apBMSCs for 1 h. Efferocytosis was measured as percentage of F4/80þ cells which were apBMSCþ. IL-10
treatment increased efferocytosis compared to vehicle control. (C) BMMs were treated for 24 h with rmIL-10 (0.1-100 ng/mL) and co-cultured with apoptotic BMSCs for 1 h.
IL-10 (1.0–100 ng/mL) increased efferocytosis of apBMSCs. (D) BMMs were treated with IL-10 (10 ng/mL) for 4–48 h and co-cultured with apBMSCs for 1 h. Treatment of
macrophages with rmIL-10 for 24–48 h induced a larger increase in efferocytosis relative to shorter treatment times. (E) BMMs treated for 24 h with IL-10 or vehicle control and
co-cultured with apoptotic BMSCs for 0.5–12 h. IL-10 increased engulfment of apBMSCs after 0.5–2 h co-culture. n¼ 6/gp, data is mean SEM. P< 0.05, P< 0.01 versus
vehicle treatment.
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mediate pro-inflammatory or anti-inflammatory conditions yet little
is known about their role in the basic cell biology of bone.
Macrophages have recently become of interest in the bone field
due to their intimate association with the bone forming unit and
contributions to osteoblast function [Chang et al., 2008; Alexander
et al., 2011; Cho et al., 2014]. It is hypothesized that the anti-
inflammatory function of macrophages and the clearance of
apoptotic cells may contribute to bone turnover and regeneration
[McCauley et al., 2014]. In humans, billions of cells die daily which is
unappreciated by currentmethods used to detect apoptotic cells from
in vivo tissue samples. This is due to the rapid and effective clearance
of apoptotic cells, termed efferocytosis [Ravichandran and Lorenz,
2007]. Macrophages are vital mediators of cellular turnover,
maintenance of extracellular matrix homeostasis and modulation,
and resolution of inflammation [Hasturk et al., 2012]. Understanding
their mechanisms of action as they relate to bone remodeling
Fig. 2. IL-10 polarizes BMMs to alternatively activated (M2) phenotype. (A) BMMs were treated with rmIL-10 (10 ng/mL) for 24 h and enumerated. IL-10 did not change cell
number compared to vehicle controls or viability, (B) BMMs treated for 24 h with rmIL-10 were analyzed via FACs for phagocytic cells (CD68) and M1 macrophage phenotype
(CD86). No significant changes were observed in these cell populations with IL-10 treatment. (C) BMMs treated with IL-10 were analyzed via FACs analysis for alternatively
activated M2 macrophages (CD206). IL-10 treatment significantly increased the CD206hi population per CD206þ. (D) BMMs treated with IL-10 showed enhanced efferocytosis
of apBMSCs within the CD206þ population after 1 h co-culture as evidences by increased CD206þapBMSCsþ double positive cells. n¼ 6/gp, data is mean SEM. P< 0.01,
P<0.001 versus vehicle treatment.
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Fig. 3. Stat3 inhibition diminished IL-10 effect. (A) BM cells were harvested from4- to 8-week old hCD68-GFPmice, enriched tomacrophageswithM-CSF then analyzed for GFP retention.
FACs analysis showed that the majority of CD68-PEþ cells were also GFPþ, indicating GFP was retained during in vitro culture. (B) hCD68-GFP BMMs were treated with IL-10 for 24h and
efferocytosis of apBMSCs harvested from C57BL/6J analyzed via FACs analysis. IL-10 significantly increased the percentage of GFPþ cells whichwere also positive for apBMSCs (Deep Red). (C)
hCD68-GFPBMMswere treatedwith IL-10 for24handefferocytosis of apBMSCs analyzedvia confocalmicroscopy. (D)hCD68-GFPBMMswere treatedwithStat3 inhibitor (Stattic, 6.25mM)
orDMSOfor2hfollowedby IL-10orvehicle treatment for24h.EfferocytosisofapBMSCswasanalyzedviaFACsanalysis fordoublepositiveGFP/apBMSCscells (representativedotplots on left).
Stat3 inhibitor decreased efferocytosis of apBMSCs in vehicle and IL-10 treatedBMMs. (E)Alternatively activatedmacrophagephenotype (CD206-PE)was increased in IL-10 treatedBMMsand
the effect was diminished with Stattic pre-treatment. n¼ 6/group, data is mean SEM. P< 0.05, P< 0.01, P< 0.001 versus vehicle treatment.
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provides a basis for the prevention and treatment of chronic
inflammatory conditions.
Anti-inflammatory cytokines such as IL-4 and IL-10 released by
immune cells have been shown to increase human peripheral blood
macrophage engulfment of non-bone associated apoptotic cells
[Ogden et al., 2005; Lingnau et al., 2007]. IL-10 contributes to bone
turnover by regulating osteoclastogenesis and IL-10 deficient mice
display osteopenia [Dresner-Pollak et al., 2004; Fujioka et al., 2015],
but the role of IL-10-associated efferocytosis by bone marrow
macrophages is largely unknown. To study mechanisms of
efferocytosis in bone marrow derived macrophages, a series of in
vitro experiments were performed to determine how bone macro-
phages respond to apoptotic bone marrow stromal cells and what
factors may influence the rate of engulfment. IL-10 treated
macrophages displayed enhanced clearance of apoptotic bone
marrow stromal cells. The effect of IL-10 on bone marrow
macrophages was in part due to polarization of macrophages
toward the pro-resolving M2 phenotype. While there was a
significant increase in M2 macrophages, the increase was not the
only contributing factor to an increase in efferocytosis. The CD206þ
M2macrophages displayed increased efferocytosis of apoptotic bone
cells after treatment with IL-10 compared to vehicle treated
macrophages. This suggests that not only does IL-10 polarize
macrophages to M2, but it also enhances the M2 macrophage
efferocytic capacity.
The effect of IL-10 on efferocytosis of apoptotic lymphocytes and
neutrophils has been measured, and downstream signaling of IL-10
has been identified [Ogden et al., 2005; Lingnau et al., 2007]. IL-10
signals through the JAK/STAT pathway, in which STAT3 is
phosphorylated, dimerizes, and translocates to the nucleus to
Fig. 4. Macrophage efferocytosis induces CCL2 and TGF-b1 secretion. (A) Supernatants were harvested from BMMs, apBMSCs or co-culture of BMMs with apBMSCs for 18 h
and analyzed for secreted proteins using a murine inflammatory cytokine array. Co-culture of BMMs with apBMSCs showed significantly increased secreted CCL2 compared to
BMMs or apBMSCs cultured alone (arbitrary units, a.u.). (B) RNA was isolated from BMMs alone or co-cultured with apBMSCs or apoptotic neutrophils and QRT-PCR performed
for ccl2 mRNA. Ccl2 gene expression was increased in co-culture of BMMswith apBMSCs compared to BMMs alone. (C) ELISA for total TGF-b1 levels in the supernatants showed
increased secreted TGF-b1 after 18 h of co-culture of BMMs with apBMSCs compared to BMMs, n¼ 6/gp data is mean SEM. P< 0.05, P< 0.001 versus macrophages
cultured alone.
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regulate transcription of various genes [Liu et al., 1994; Donnelly
et al., 1999; Lang et al., 2002]. To validate the downstream events of
IL-10 signaling, macrophages were treated with an inhibitor of
STAT3 phosphorylation (Stattic) prior to IL-10 treatment. Effer-
ocytosis of apoptotic bone cells was decreasedwith Stattic treatment,
demonstrating that the IL-10 effect occurs in a pSTAT3-dependent
manner. Previous studies have also indicated that inhibition of
STAT3 phosphorlyation decreases MFG-E8 mediated phagocytosis
of apoptotic mimicry beads [Soki et al., 2014].
Following IL-10 activation of macrophages and efferocytosis of
apoptotic bone cells, proteins released by macrophages signal to
surrounding cells. Howmacrophages respond to apoptotic bone cells
may indicate what effects efferocytosis have on bone modeling and
remodeling. The identity of the apoptotic cell, bone marrow stromal
cells in this case, contributes to the profile of genes upregulated in
macrophages partaking in efferocytosis. In the present study, bone
marrow derived macrophages increased secretion of monocyte
chemoattractant protein-1/CC chemokine ligand 2 (MCP-1/CCL2)
after co-culture with apoptotic bone cells. CCL2 is associated with
monocyte/osteoclast precursor recruitment and enhances osteoclas-
togenesis [Li et al., 2007]. These data suggest that CCL2 secreted from
macrophages engulfing apoptotic bone cells could aid in the
recruitment of monocytes to enhance bone turnover by increasing
osteoclasts and bone macrophages.
TGF-b1 was also found to be increased after efferocytosis of
apBMSCs. Previous studies using human peripheral blood macro-
phages showed increased TGF-b1 levels following efferocytosis of
apoptotic human derived neutrophils [Fadok et al., 1998]. The release
of TGF-b1 following apoptotic cell engulfment is often credited with
an anti-inflammatory function. Interestingly, in the context of bone,
TGF-b1 enhances the recruitment of mesenchymal stem cells which
are precursors to osteoblastic cells [Tang et al., 2009; Koh et al.,
2011]. The secretion of TGF-b1 in response to apoptotic bone cells
may contribute to repopulating the bone forming units. Other
osteogenic factors such as BMP-2 and osteopontin have been
shown to be released from M2 macrophages, but it is unclear how
the protein levels change during the process of efferocytosis
[Takahashi et al., 2004; Honda et al., 2006].
Macrophages are crucial regulators of bone turnover in steady
state bone remodeling and wound healing [Chang et al., 2008;
Alexander et al., 2011]. A better understanding of the role of these
macrophages is important in developing ways to utilize macro-
phages in therapeutic interventions for osteoporosis, fracture
healing, periodontal wound healing, and osteonecrosis. These data
demonstrate one mechanism by which macrophages efferocytose
apoptotic bone cells and their subsequent release of factors
important in bone remodeling (Fig. 5). Future work to determine
the association of efferocytosis and bone turnover is important to
better understand themechanisms bywhichmacrophages contribute
to bone modeling and remodeling.
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